Your browser doesn't support javascript.
loading
Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States.
Armbrecht, Eric; Shah, Anuj; Schepman, Patricia; Shah, Ruchit; Pappadopulos, Elizabeth; Chambers, Richard; Stephens, Jennifer; Haider, Seema; McIntyre, Roger S.
Afiliação
  • Armbrecht E; Saint Louis University Center for Health Outcomes Research, St. Louis, MO, USA.
  • Shah A; Pharmerit International, Bethesda, MD, USA.
  • Schepman P; Pfizer Inc, New York, NY, USA.
  • Shah R; Pharmerit International, Bethesda, MD, USA.
  • Pappadopulos E; Pfizer Inc, New York, NY, USA.
  • Chambers R; Pfizer Inc, New York, NY, USA.
  • Stephens J; Pharmerit International, Bethesda, MD, USA.
  • Haider S; Pfizer Inc, New York, NY, USA.
  • McIntyre RS; Mood Disorders Psychopharmacology Unit, University of Toronto, Toronto, ON, Canada.
J Med Econ ; 23(9): 1032-1042, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32468879
ABSTRACT

Aims:

This study estimated the economic and humanistic burden associated with chronic non-communicable diseases (NCCDs) among adults with comorbid major depressive and/or any anxiety disorders (MDD and/or AAD).Materials and

methods:

A retrospective analysis was conducted using the Medical Expenditure Panel Survey data (2010-2015). The analytic cohort included adults (≥18 years) with MDD only (C1), AAD only (C2), or both (C3). The presence of either of 6 NCCDs (cardiovascular diseases [CVD], pulmonary disorders [PD], pain, high cholesterol, diabetes, and obesity) were assessed. Study outcomes included healthcare costs, activity limitations, and quality of life. Multivariate regressions were conducted in each of the 3 cohorts to evaluate the association between the presence of NCCDs and outcomes.

Results:

The analytic sample included 9,160,465 patients C1 (4,391,738), C2 (3,648,436), C3 (1,120,292). Pain (59%) was the most common condition, followed by CVD (55%), high cholesterol (50%), obesity (42%), PD (17%), and diabetes (14%). Mean annual healthcare costs were the greatest for C3 ($14,317), followed by C1 ($10,490) and C2 ($7,906). For C1, CVD was associated with the highest increment in annual costs ($3,966) followed by pain ($3,617). For C2, diabetes was associated with the highest incremental annual costs ($4,281) followed by PD ($2,997). For C3, cost trends were similar to those seen in C2. NCCDs resulted in a significant decrease in physical quality of life across all cohorts. Pain was associated with a significantly higher likelihood of self-reported physical, social, cognitive, and activity limitations compared to those without pain.

Conclusions:

60% of patients with MDD and/or AAD had at least one additional NCCD, which significantly increased the economic and humanistic burden. These findings are important for payers and clinicians in making treatment decisions. These results underscore the need for development of multi-pronged interventions which aim to improve quality of life and reduce activity limitations among patients with mental health disorders and NCCDs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos de Ansiedade / Transtorno Depressivo Maior / Doenças não Transmissíveis Tipo de estudo: Health_economic_evaluation / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos de Ansiedade / Transtorno Depressivo Maior / Doenças não Transmissíveis Tipo de estudo: Health_economic_evaluation / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article